Cardiovascular Risk in Rheumatic Patients Treated with JAK Inhibitors: The Role of Traditional and Emerging Biomarkers in a Pilot Study.

J Clin Med · 2025 · PMC12347378 · PMID 40807052

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Of note, BMI showed only a borderline significant association; thus, this result should be interpreted with caution.

also in 11,409 other papers

did not reach statistical significanceno p-value reported

Some results did not reach statistical significance due to limited power, and we could not rigorously compare the effects of different JAKi drugs (tofacitinib vs. baricitinib vs. upadacitinib) on cardiovascular outcomes.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.